nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—polycystic ovary syndrome—Ethinyl Estradiol—osteoporosis	0.408	1	CpDpCtD
Drospirenone—AR—Ergocalciferol—osteoporosis	0.0978	0.442	CbGbCtD
Drospirenone—Formestane—Estropipate—osteoporosis	0.093	0.351	CrCrCtD
Drospirenone—PTGS2—Risedronate—osteoporosis	0.0725	0.328	CbGbCtD
Drospirenone—Formestane—Conjugated Estrogens—osteoporosis	0.0705	0.266	CrCrCtD
Drospirenone—AR—Estradiol—osteoporosis	0.0508	0.23	CbGbCtD
Drospirenone—Norethindrone—Ethinyl Estradiol—osteoporosis	0.0394	0.149	CrCrCtD
Drospirenone—Methyltestosterone—Ethinyl Estradiol—osteoporosis	0.0323	0.122	CrCrCtD
Drospirenone—Testosterone—Estradiol—osteoporosis	0.0295	0.111	CrCrCtD
Drospirenone—Vascular occlusion—Ethinyl Estradiol—osteoporosis	0.0105	0.13	CcSEcCtD
Drospirenone—Venous occlusion—Ethinyl Estradiol—osteoporosis	0.00698	0.0864	CcSEcCtD
Drospirenone—Thromboembolic event—Raloxifene—osteoporosis	0.00223	0.0276	CcSEcCtD
Drospirenone—Venous thromboembolism—Raloxifene—osteoporosis	0.00205	0.0253	CcSEcCtD
Drospirenone—Thromboembolic event—Ethinyl Estradiol—osteoporosis	0.00187	0.0231	CcSEcCtD
Drospirenone—Infarction—Ethinyl Estradiol—osteoporosis	0.00181	0.0224	CcSEcCtD
Drospirenone—Uterine haemorrhage—Estropipate—osteoporosis	0.00178	0.022	CcSEcCtD
Drospirenone—Uterine haemorrhage—Raloxifene—osteoporosis	0.00172	0.0213	CcSEcCtD
Drospirenone—Venous thromboembolism—Ethinyl Estradiol—osteoporosis	0.00171	0.0212	CcSEcCtD
Drospirenone—Cerebral infarction—Ethinyl Estradiol—osteoporosis	0.00154	0.0191	CcSEcCtD
Drospirenone—Uterine haemorrhage—Ethinyl Estradiol—osteoporosis	0.00144	0.0178	CcSEcCtD
Drospirenone—Embolism venous—Estropipate—osteoporosis	0.00123	0.0152	CcSEcCtD
Drospirenone—Embolism venous—Raloxifene—osteoporosis	0.00119	0.0147	CcSEcCtD
Drospirenone—Uterine haemorrhage—Conjugated Estrogens—osteoporosis	0.00117	0.0145	CcSEcCtD
Drospirenone—Loss of libido—Ethinyl Estradiol—osteoporosis	0.00109	0.0135	CcSEcCtD
Drospirenone—Embolism venous—Ethinyl Estradiol—osteoporosis	0.000997	0.0123	CcSEcCtD
Drospirenone—Embolism—Estropipate—osteoporosis	0.000967	0.012	CcSEcCtD
Drospirenone—Uterine haemorrhage—Estradiol—osteoporosis	0.000939	0.0116	CcSEcCtD
Drospirenone—Embolism—Raloxifene—osteoporosis	0.000936	0.0116	CcSEcCtD
Drospirenone—Thrombosis—Estropipate—osteoporosis	0.000877	0.0108	CcSEcCtD
Drospirenone—Embolism venous—Conjugated Estrogens—osteoporosis	0.000813	0.01	CcSEcCtD
Drospirenone—Embolism—Ethinyl Estradiol—osteoporosis	0.000784	0.00969	CcSEcCtD
Drospirenone—Breast pain—Estropipate—osteoporosis	0.000711	0.0088	CcSEcCtD
Drospirenone—Loss of libido—Estradiol—osteoporosis	0.000711	0.00879	CcSEcCtD
Drospirenone—Thrombosis—Ethinyl Estradiol—osteoporosis	0.000711	0.00879	CcSEcCtD
Drospirenone—Breast pain—Raloxifene—osteoporosis	0.000689	0.00852	CcSEcCtD
Drospirenone—Embolism venous—Estradiol—osteoporosis	0.00065	0.00804	CcSEcCtD
Drospirenone—Embolism—Conjugated Estrogens—osteoporosis	0.000639	0.0079	CcSEcCtD
Drospirenone—Thrombosis—Conjugated Estrogens—osteoporosis	0.000579	0.00716	CcSEcCtD
Drospirenone—Breast pain—Ethinyl Estradiol—osteoporosis	0.000577	0.00713	CcSEcCtD
Drospirenone—Embolism—Estradiol—osteoporosis	0.000511	0.00632	CcSEcCtD
Drospirenone—Breast pain—Conjugated Estrogens—osteoporosis	0.00047	0.00581	CcSEcCtD
Drospirenone—Thrombosis—Estradiol—osteoporosis	0.000464	0.00573	CcSEcCtD
Drospirenone—Cerebrovascular accident—Estropipate—osteoporosis	0.00046	0.00569	CcSEcCtD
Drospirenone—Cerebrovascular accident—Raloxifene—osteoporosis	0.000445	0.00551	CcSEcCtD
Drospirenone—Migraine—Estropipate—osteoporosis	0.000443	0.00548	CcSEcCtD
Drospirenone—Migraine—Raloxifene—osteoporosis	0.000429	0.00531	CcSEcCtD
Drospirenone—Mood swings—Estropipate—osteoporosis	0.000427	0.00528	CcSEcCtD
Drospirenone—Migraine—Ibandronate—osteoporosis	0.000425	0.00526	CcSEcCtD
Drospirenone—Breast disorder—Estropipate—osteoporosis	0.000407	0.00503	CcSEcCtD
Drospirenone—Breast disorder—Raloxifene—osteoporosis	0.000394	0.00488	CcSEcCtD
Drospirenone—Breast disorder—Ibandronate—osteoporosis	0.00039	0.00483	CcSEcCtD
Drospirenone—Breast pain—Estradiol—osteoporosis	0.000376	0.00465	CcSEcCtD
Drospirenone—Cerebrovascular accident—Ethinyl Estradiol—osteoporosis	0.000373	0.00461	CcSEcCtD
Drospirenone—Migraine—Ethinyl Estradiol—osteoporosis	0.000359	0.00444	CcSEcCtD
Drospirenone—Affect lability—Ethinyl Estradiol—osteoporosis	0.000359	0.00444	CcSEcCtD
Drospirenone—Testolactone—CYP19A1—osteoporosis	0.000353	0.175	CrCbGaD
Drospirenone—Depression—Estropipate—osteoporosis	0.000346	0.00428	CcSEcCtD
Drospirenone—Mood swings—Ethinyl Estradiol—osteoporosis	0.000346	0.00428	CcSEcCtD
Drospirenone—Acute coronary syndrome—Estropipate—osteoporosis	0.000342	0.00423	CcSEcCtD
Drospirenone—Erythema multiforme—Etidronic acid—osteoporosis	0.000341	0.00421	CcSEcCtD
Drospirenone—Myocardial infarction—Estropipate—osteoporosis	0.00034	0.00421	CcSEcCtD
Drospirenone—Depression—Raloxifene—osteoporosis	0.000335	0.00415	CcSEcCtD
Drospirenone—Depression—Ibandronate—osteoporosis	0.000332	0.00411	CcSEcCtD
Drospirenone—Breast disorder—Ethinyl Estradiol—osteoporosis	0.00033	0.00408	CcSEcCtD
Drospirenone—Breast disorder—Risedronate—osteoporosis	0.000322	0.00398	CcSEcCtD
Drospirenone—Haemoglobin—Alendronate—osteoporosis	0.000308	0.00382	CcSEcCtD
Drospirenone—Haemorrhage—Alendronate—osteoporosis	0.000307	0.0038	CcSEcCtD
Drospirenone—Cerebrovascular accident—Conjugated Estrogens—osteoporosis	0.000304	0.00376	CcSEcCtD
Drospirenone—Haemoglobin—Ibandronate—osteoporosis	0.0003	0.00371	CcSEcCtD
Drospirenone—Haemorrhage—Ibandronate—osteoporosis	0.000299	0.0037	CcSEcCtD
Drospirenone—Erythema multiforme—Estropipate—osteoporosis	0.000295	0.00364	CcSEcCtD
Drospirenone—Haemoglobin—Calcitriol—osteoporosis	0.000294	0.00364	CcSEcCtD
Drospirenone—Migraine—Conjugated Estrogens—osteoporosis	0.000293	0.00362	CcSEcCtD
Drospirenone—Haemorrhage—Calcitriol—osteoporosis	0.000293	0.00362	CcSEcCtD
Drospirenone—Erythema multiforme—Alendronate—osteoporosis	0.00029	0.00359	CcSEcCtD
Drospirenone—Angiopathy—Estropipate—osteoporosis	0.000283	0.0035	CcSEcCtD
Drospirenone—Mood swings—Conjugated Estrogens—osteoporosis	0.000282	0.00349	CcSEcCtD
Drospirenone—Depression—Ethinyl Estradiol—osteoporosis	0.000281	0.00347	CcSEcCtD
Drospirenone—Acute coronary syndrome—Ethinyl Estradiol—osteoporosis	0.000277	0.00343	CcSEcCtD
Drospirenone—Erythema multiforme—Calcitriol—osteoporosis	0.000277	0.00342	CcSEcCtD
Drospirenone—Myocardial infarction—Ethinyl Estradiol—osteoporosis	0.000276	0.00341	CcSEcCtD
Drospirenone—Angiopathy—Raloxifene—osteoporosis	0.000274	0.00339	CcSEcCtD
Drospirenone—Depression—Risedronate—osteoporosis	0.000274	0.00338	CcSEcCtD
Drospirenone—Mental disorder—Estropipate—osteoporosis	0.000273	0.00338	CcSEcCtD
Drospirenone—Angiopathy—Ibandronate—osteoporosis	0.000271	0.00335	CcSEcCtD
Drospirenone—Breast disorder—Conjugated Estrogens—osteoporosis	0.000269	0.00333	CcSEcCtD
Drospirenone—Mental disorder—Ibandronate—osteoporosis	0.000262	0.00324	CcSEcCtD
Drospirenone—Haemoglobin—Ethinyl Estradiol—osteoporosis	0.000254	0.00314	CcSEcCtD
Drospirenone—Haemorrhage—Ethinyl Estradiol—osteoporosis	0.000253	0.00312	CcSEcCtD
Drospirenone—Haemoglobin—Risedronate—osteoporosis	0.000248	0.00306	CcSEcCtD
Drospirenone—Haemorrhage—Risedronate—osteoporosis	0.000246	0.00305	CcSEcCtD
Drospirenone—Cerebrovascular accident—Estradiol—osteoporosis	0.000243	0.00301	CcSEcCtD
Drospirenone—Erythema multiforme—Ethinyl Estradiol—osteoporosis	0.000239	0.00295	CcSEcCtD
Drospirenone—Depression—Zoledronate—osteoporosis	0.000238	0.00294	CcSEcCtD
Drospirenone—Haemoglobin—Pamidronate—osteoporosis	0.000235	0.00291	CcSEcCtD
Drospirenone—Migraine—Estradiol—osteoporosis	0.000234	0.0029	CcSEcCtD
Drospirenone—Affect lability—Estradiol—osteoporosis	0.000234	0.0029	CcSEcCtD
Drospirenone—Haemorrhage—Pamidronate—osteoporosis	0.000234	0.0029	CcSEcCtD
Drospirenone—Nausea—Calcium Acetate—osteoporosis	0.000232	0.00286	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.000229	0.00284	CcSEcCtD
Drospirenone—Angiopathy—Ethinyl Estradiol—osteoporosis	0.000229	0.00283	CcSEcCtD
Drospirenone—Depression—Conjugated Estrogens—osteoporosis	0.000229	0.00283	CcSEcCtD
Drospirenone—Acute coronary syndrome—Conjugated Estrogens—osteoporosis	0.000226	0.0028	CcSEcCtD
Drospirenone—Mood swings—Estradiol—osteoporosis	0.000226	0.00279	CcSEcCtD
Drospirenone—Myocardial infarction—Conjugated Estrogens—osteoporosis	0.000225	0.00278	CcSEcCtD
Drospirenone—Angiopathy—Risedronate—osteoporosis	0.000223	0.00276	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000222	0.00275	CcSEcCtD
Drospirenone—Spironolactone—SHBG—osteoporosis	0.000222	0.11	CrCbGaD
Drospirenone—Mental disorder—Ethinyl Estradiol—osteoporosis	0.000221	0.00274	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00022	0.00272	CcSEcCtD
Drospirenone—Nervous system disorder—Estropipate—osteoporosis	0.000217	0.00269	CcSEcCtD
Drospirenone—Mental disorder—Risedronate—osteoporosis	0.000216	0.00267	CcSEcCtD
Drospirenone—Breast disorder—Estradiol—osteoporosis	0.000215	0.00266	CcSEcCtD
Drospirenone—Skin disorder—Estropipate—osteoporosis	0.000215	0.00266	CcSEcCtD
Drospirenone—Angiopathy—Pamidronate—osteoporosis	0.000212	0.00263	CcSEcCtD
Drospirenone—Nervous system disorder—Raloxifene—osteoporosis	0.00021	0.0026	CcSEcCtD
Drospirenone—Skin disorder—Raloxifene—osteoporosis	0.000208	0.00258	CcSEcCtD
Drospirenone—Nervous system disorder—Ibandronate—osteoporosis	0.000208	0.00258	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—SHBG—osteoporosis	0.000208	0.103	CrCbGaD
Drospirenone—Skin disorder—Ibandronate—osteoporosis	0.000206	0.00255	CcSEcCtD
Drospirenone—Norethindrone—SHBG—osteoporosis	0.000206	0.102	CrCbGaD
Drospirenone—Nausea—Ergocalciferol—osteoporosis	0.000205	0.00253	CcSEcCtD
Drospirenone—Skin disorder—Calcitriol—osteoporosis	0.000202	0.0025	CcSEcCtD
Drospirenone—Methyltestosterone—SHBG—osteoporosis	0.000195	0.0972	CrCbGaD
Drospirenone—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.000195	0.00241	CcSEcCtD
Drospirenone—Angiopathy—Zoledronate—osteoporosis	0.000194	0.0024	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Estropipate—osteoporosis	0.000191	0.00236	CcSEcCtD
Drospirenone—Mental disorder—Zoledronate—osteoporosis	0.000187	0.00232	CcSEcCtD
Drospirenone—Angiopathy—Conjugated Estrogens—osteoporosis	0.000187	0.00231	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000186	0.0023	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000185	0.00229	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000183	0.00227	CcSEcCtD
Drospirenone—Depression—Estradiol—osteoporosis	0.000183	0.00226	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000181	0.00224	CcSEcCtD
Drospirenone—Acute coronary syndrome—Estradiol—osteoporosis	0.000181	0.00224	CcSEcCtD
Drospirenone—Mental disorder—Conjugated Estrogens—osteoporosis	0.00018	0.00223	CcSEcCtD
Drospirenone—Myocardial infarction—Estradiol—osteoporosis	0.00018	0.00223	CcSEcCtD
Drospirenone—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000176	0.00218	CcSEcCtD
Drospirenone—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000174	0.00216	CcSEcCtD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	0.000173	0.00723	CbGpPWpGaD
Drospirenone—PGR—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000172	0.00719	CbGpPWpGaD
Drospirenone—Nervous system disorder—Risedronate—osteoporosis	0.000172	0.00212	CcSEcCtD
Drospirenone—AR—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.000171	0.00716	CbGpPWpGaD
Drospirenone—Skin disorder—Risedronate—osteoporosis	0.00017	0.0021	CcSEcCtD
Drospirenone—AR—Nuclear Receptors—ESR1—osteoporosis	0.000166	0.00693	CbGpPWpGaD
Drospirenone—Haemoglobin—Estradiol—osteoporosis	0.000166	0.00205	CcSEcCtD
Drospirenone—Haemorrhage—Estradiol—osteoporosis	0.000165	0.00204	CcSEcCtD
Drospirenone—PGR—Cellular roles of Anthrax toxin—TNF—osteoporosis	0.000163	0.00682	CbGpPWpGaD
Drospirenone—Nervous system disorder—Pamidronate—osteoporosis	0.000163	0.00202	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000157	0.00195	CcSEcCtD
Drospirenone—Erythema multiforme—Estradiol—osteoporosis	0.000156	0.00193	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000155	0.00192	CcSEcCtD
Drospirenone—Nausea—Etidronic acid—osteoporosis	0.000152	0.00188	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000152	0.00187	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Risedronate—osteoporosis	0.000151	0.00187	CcSEcCtD
Drospirenone—Angiopathy—Estradiol—osteoporosis	0.00015	0.00185	CcSEcCtD
Drospirenone—Nervous system disorder—Zoledronate—osteoporosis	0.000149	0.00184	CcSEcCtD
Drospirenone—Skin disorder—Zoledronate—osteoporosis	0.000148	0.00183	CcSEcCtD
Drospirenone—AR—FOXA1 transcription factor network—ESR1—osteoporosis	0.000147	0.00616	CbGpPWpGaD
Drospirenone—Hydrocortisone—SHBG—osteoporosis	0.000147	0.0732	CrCbGaD
Drospirenone—Mental disorder—Estradiol—osteoporosis	0.000144	0.00179	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000144	0.00178	CcSEcCtD
Drospirenone—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000143	0.00177	CcSEcCtD
Drospirenone—Methyltestosterone—CYP19A1—osteoporosis	0.000143	0.0713	CrCbGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—ESR1—osteoporosis	0.000143	0.00599	CbGpPWpGaD
Drospirenone—Skin disorder—Conjugated Estrogens—osteoporosis	0.000142	0.00176	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—ESR1—osteoporosis	0.00014	0.0697	CrCbGaD
Drospirenone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	0.000136	0.00569	CbGpPWpGaD
Drospirenone—Nausea—Estropipate—osteoporosis	0.000132	0.00163	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000131	0.00162	CcSEcCtD
Drospirenone—AR—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000131	0.00547	CbGpPWpGaD
Drospirenone—Nausea—Alendronate—osteoporosis	0.00013	0.0016	CcSEcCtD
Drospirenone—Nausea—Raloxifene—osteoporosis	0.000127	0.00158	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000127	0.00532	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	0.000127	0.00532	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000126	0.00156	CcSEcCtD
Drospirenone—Nausea—Ibandronate—osteoporosis	0.000126	0.00156	CcSEcCtD
Drospirenone—Nausea—Calcitriol—osteoporosis	0.000123	0.00153	CcSEcCtD
Drospirenone—BCHE—Peptide hormone metabolism—ACE—osteoporosis	0.000123	0.00512	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000121	0.0015	CcSEcCtD
Drospirenone—PTGS2—C-MYB transcription factor network—COL1A2—osteoporosis	0.00012	0.00502	CbGpPWpGaD
Drospirenone—Progesterone—SHBG—osteoporosis	0.00012	0.0596	CrCbGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	0.000118	0.00495	CbGpPWpGaD
Drospirenone—Nervous system disorder—Estradiol—osteoporosis	0.000115	0.00142	CcSEcCtD
Drospirenone—Skin disorder—Estradiol—osteoporosis	0.000114	0.00141	CcSEcCtD
Drospirenone—Testosterone—SHBG—osteoporosis	0.000113	0.0564	CrCbGaD
Drospirenone—PGR—Signaling by ERBB4—KL—osteoporosis	0.000112	0.00468	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—WNT1—osteoporosis	0.000109	0.00456	CbGpPWpGaD
Drospirenone—Nausea—Ethinyl Estradiol—osteoporosis	0.000107	0.00132	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000105	0.00441	CbGpPWpGaD
Drospirenone—Nausea—Risedronate—osteoporosis	0.000104	0.00129	CcSEcCtD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	0.000102	0.00425	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Estradiol—osteoporosis	0.000101	0.00125	CcSEcCtD
Drospirenone—NR3C2—Gene Expression—U2AF1—osteoporosis	0.000101	0.00422	CbGpPWpGaD
Drospirenone—Nausea—Pamidronate—osteoporosis	9.88e-05	0.00122	CcSEcCtD
Drospirenone—PTGS2—Arachidonic acid metabolism—GPX1—osteoporosis	9.32e-05	0.0039	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	9.04e-05	0.00378	CbGpPWpGaD
Drospirenone—Nausea—Zoledronate—osteoporosis	9.02e-05	0.00112	CcSEcCtD
Drospirenone—AR—SIDS Susceptibility Pathways—ESR2—osteoporosis	8.83e-05	0.00369	CbGpPWpGaD
Drospirenone—Nausea—Conjugated Estrogens—osteoporosis	8.69e-05	0.00107	CcSEcCtD
Drospirenone—Testosterone—CYP19A1—osteoporosis	8.32e-05	0.0414	CrCbGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	8.23e-05	0.00344	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	8.18e-05	0.00342	CbGpPWpGaD
Drospirenone—Progesterone—ESR1—osteoporosis	8.1e-05	0.0403	CrCbGaD
Drospirenone—NR3C2—Generic Transcription Pathway—ESR2—osteoporosis	8.04e-05	0.00336	CbGpPWpGaD
Drospirenone—PTGS2—Overview of nanoparticle effects—TNF—osteoporosis	8.04e-05	0.00336	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.88e-05	0.0033	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—IRS2—osteoporosis	7.68e-05	0.00321	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—LEP—osteoporosis	7.61e-05	0.00318	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	7.51e-05	0.00314	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—RPL24—osteoporosis	7.5e-05	0.00314	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	7.47e-05	0.00312	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—MYC—osteoporosis	7.45e-05	0.00312	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—ESR1—osteoporosis	7.17e-05	0.003	CbGpPWpGaD
Drospirenone—Nausea—Estradiol—osteoporosis	6.95e-05	0.00086	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—IRS1—osteoporosis	6.7e-05	0.0028	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—POMC—osteoporosis	6.54e-05	0.00273	CbGpPWpGaD
Drospirenone—PTGS2—Overview of nanoparticle effects—IL6—osteoporosis	6.48e-05	0.00271	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CCT2—osteoporosis	6.45e-05	0.0027	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—VDR—osteoporosis	6.38e-05	0.00267	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—IL6R—osteoporosis	6.3e-05	0.00263	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—IGF1—osteoporosis	6.29e-05	0.00263	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—SOD2—osteoporosis	6.22e-05	0.0026	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—U2AF1—osteoporosis	6.15e-05	0.00257	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	6.06e-05	0.00254	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	5.93e-05	0.00248	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.81e-05	0.00243	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.66e-05	0.00237	CbGpPWpGaD
Drospirenone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	5.52e-05	0.00231	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—ESR1—osteoporosis	5.49e-05	0.0023	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—TUBA1B—osteoporosis	5.49e-05	0.00229	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	5.47e-05	0.00229	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	5.42e-05	0.00227	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.14e-05	0.00215	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—IRS1—osteoporosis	5.13e-05	0.00215	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—ESR2—osteoporosis	4.89e-05	0.00205	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—ESR1—osteoporosis	4.87e-05	0.00204	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—osteoporosis	4.75e-05	0.00199	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	4.7e-05	0.00197	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL6R—osteoporosis	4.7e-05	0.00196	CbGpPWpGaD
Drospirenone—AR—Gene Expression—U2AF1—osteoporosis	4.68e-05	0.00196	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SOST—osteoporosis	4.61e-05	0.00193	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—RPL24—osteoporosis	4.57e-05	0.00191	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	4.55e-05	0.0019	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.53e-05	0.00189	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	4.48e-05	0.00187	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—RPL24—osteoporosis	4.39e-05	0.00183	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—PSMA2—osteoporosis	4.33e-05	0.00181	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—PSMA5—osteoporosis	4.33e-05	0.00181	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	4.32e-05	0.0018	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	4.25e-05	0.00178	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CALCR—osteoporosis	4.17e-05	0.00174	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTH1R—osteoporosis	4.17e-05	0.00174	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—LEP—osteoporosis	4.03e-05	0.00169	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4e-05	0.00167	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	3.96e-05	0.00166	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.94e-05	0.00165	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	3.9e-05	0.00163	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—VDR—osteoporosis	3.88e-05	0.00162	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—ESR2—osteoporosis	3.87e-05	0.00162	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—TLN1—osteoporosis	3.86e-05	0.00161	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.85e-05	0.00161	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—ESR2—osteoporosis	3.73e-05	0.00156	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—REN—osteoporosis	3.71e-05	0.00155	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	3.71e-05	0.00155	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL1B—osteoporosis	3.57e-05	0.00149	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PKM—osteoporosis	3.51e-05	0.00147	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—FDPS—osteoporosis	3.51e-05	0.00147	CbGpPWpGaD
Drospirenone—AR—Gene Expression—RPL24—osteoporosis	3.48e-05	0.00146	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—ADCY5—osteoporosis	3.44e-05	0.00144	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PGLS—osteoporosis	3.33e-05	0.00139	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GPD2—osteoporosis	3.33e-05	0.00139	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MGLL—osteoporosis	3.31e-05	0.00139	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	3.25e-05	0.00136	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LRP5—osteoporosis	3.23e-05	0.00135	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.12e-05	0.0013	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LRP6—osteoporosis	3.09e-05	0.00129	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—VDR—osteoporosis	3.07e-05	0.00128	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PNP—osteoporosis	3.04e-05	0.00127	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ATIC—osteoporosis	3.04e-05	0.00127	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—ESR1—osteoporosis	2.97e-05	0.00124	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—VDR—osteoporosis	2.96e-05	0.00124	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PKM—osteoporosis	2.88e-05	0.00121	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SOST—osteoporosis	2.88e-05	0.00121	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—MYC—osteoporosis	2.86e-05	0.00119	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—IL6—osteoporosis	2.8e-05	0.00117	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PGLS—osteoporosis	2.73e-05	0.00114	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ANTXR2—osteoporosis	2.73e-05	0.00114	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.65e-05	0.00111	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—PSMA2—osteoporosis	2.64e-05	0.0011	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—PSMA5—osteoporosis	2.64e-05	0.0011	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	2.63e-05	0.0011	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.62e-05	0.00109	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TLN1—osteoporosis	2.61e-05	0.00109	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—TNF—osteoporosis	2.59e-05	0.00108	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CA2—osteoporosis	2.59e-05	0.00108	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—OXCT1—osteoporosis	2.59e-05	0.00108	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	2.57e-05	0.00107	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—MYC—osteoporosis	2.53e-05	0.00106	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—MGLL—osteoporosis	2.52e-05	0.00105	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PKM—osteoporosis	2.42e-05	0.00101	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—FDPS—osteoporosis	2.42e-05	0.00101	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.38e-05	0.000994	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.37e-05	0.00099	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.36e-05	0.000988	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	2.36e-05	0.000986	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—ESR2—osteoporosis	2.36e-05	0.000985	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—ESR1—osteoporosis	2.35e-05	0.000981	CbGpPWpGaD
Drospirenone—PTGS2—Disease—GSN—osteoporosis	2.32e-05	0.000972	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—ACE—osteoporosis	2.31e-05	0.000967	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GPD2—osteoporosis	2.29e-05	0.000958	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PGLS—osteoporosis	2.29e-05	0.000958	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.27e-05	0.000947	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—ESR1—osteoporosis	2.26e-05	0.000946	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—P4HB—osteoporosis	2.25e-05	0.000942	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.21e-05	0.000922	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTH—osteoporosis	2.19e-05	0.000916	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RAP1A—osteoporosis	2.15e-05	0.0009	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—IDH2—osteoporosis	2.14e-05	0.000896	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CNR2—osteoporosis	2.13e-05	0.000893	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NFATC1—osteoporosis	2.1e-05	0.000878	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PNP—osteoporosis	2.09e-05	0.000876	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ATIC—osteoporosis	2.09e-05	0.000876	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL6—osteoporosis	2.09e-05	0.000875	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—DKK1—osteoporosis	2.08e-05	0.000871	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LRP5—osteoporosis	2.02e-05	0.000846	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP27A1—osteoporosis	2.02e-05	0.000843	CbGpPWpGaD
Drospirenone—AR—Gene Expression—PSMA2—osteoporosis	2.01e-05	0.00084	CbGpPWpGaD
Drospirenone—AR—Gene Expression—PSMA5—osteoporosis	2.01e-05	0.00084	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—WNT1—osteoporosis	2.01e-05	0.000839	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—MYC—osteoporosis	2e-05	0.000837	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	2e-05	0.000835	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ACP5—osteoporosis	1.96e-05	0.00082	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGA—osteoporosis	1.95e-05	0.000816	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.94e-05	0.000809	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LRP6—osteoporosis	1.93e-05	0.000809	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	1.9e-05	0.000795	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—VDR—osteoporosis	1.87e-05	0.000782	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TNF—osteoporosis	1.86e-05	0.00078	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RPL24—osteoporosis	1.86e-05	0.000777	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LTF—osteoporosis	1.86e-05	0.000777	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TPI1—osteoporosis	1.82e-05	0.000762	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—BMP2—osteoporosis	1.82e-05	0.000759	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTHLH—osteoporosis	1.82e-05	0.000759	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ESR2—osteoporosis	1.8e-05	0.000751	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CA2—osteoporosis	1.78e-05	0.000745	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—OXCT1—osteoporosis	1.78e-05	0.000745	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGB—osteoporosis	1.78e-05	0.000743	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MGLL—osteoporosis	1.74e-05	0.000726	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PSMA2—osteoporosis	1.71e-05	0.000717	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PSMA5—osteoporosis	1.71e-05	0.000717	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—P4HB—osteoporosis	1.71e-05	0.000717	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GAPDH—osteoporosis	1.68e-05	0.000703	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—RAP1A—osteoporosis	1.64e-05	0.000685	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.64e-05	0.000684	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ACP5—osteoporosis	1.61e-05	0.000674	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CALCA—osteoporosis	1.6e-05	0.000668	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—MYC—osteoporosis	1.54e-05	0.000646	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL6—osteoporosis	1.5e-05	0.000629	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TPI1—osteoporosis	1.5e-05	0.000626	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—IDH2—osteoporosis	1.48e-05	0.000617	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KL—osteoporosis	1.45e-05	0.000607	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—LEP—osteoporosis	1.44e-05	0.000601	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—ESR1—osteoporosis	1.43e-05	0.000598	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.43e-05	0.000597	CbGpPWpGaD
Drospirenone—AR—Gene Expression—VDR—osteoporosis	1.42e-05	0.000596	CbGpPWpGaD
Drospirenone—PTGS2—Disease—P4HB—osteoporosis	1.41e-05	0.000589	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP27A1—osteoporosis	1.39e-05	0.00058	CbGpPWpGaD
Drospirenone—PTGS2—Disease—GAPDH—osteoporosis	1.38e-05	0.000578	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.36e-05	0.000569	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.36e-05	0.000568	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ACP5—osteoporosis	1.35e-05	0.000564	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.33e-05	0.000557	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ENO1—osteoporosis	1.32e-05	0.000554	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NFATC1—osteoporosis	1.31e-05	0.000549	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PSMA5—osteoporosis	1.31e-05	0.000546	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PSMA2—osteoporosis	1.31e-05	0.000546	CbGpPWpGaD
Drospirenone—PTGS2—Disease—DKK1—osteoporosis	1.3e-05	0.000545	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.27e-05	0.00053	CbGpPWpGaD
Drospirenone—PTGS2—Disease—WNT1—osteoporosis	1.26e-05	0.000525	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TPI1—osteoporosis	1.25e-05	0.000525	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—POMC—osteoporosis	1.23e-05	0.000516	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGA—osteoporosis	1.22e-05	0.000511	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—MYC—osteoporosis	1.22e-05	0.00051	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—IGF1—osteoporosis	1.19e-05	0.000497	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—P4HB—osteoporosis	1.18e-05	0.000493	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—MYC—osteoporosis	1.18e-05	0.000492	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GAPDH—osteoporosis	1.16e-05	0.000484	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ADCY5—osteoporosis	1.14e-05	0.000475	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—RAP1A—osteoporosis	1.13e-05	0.000472	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SPP1—osteoporosis	1.1e-05	0.00046	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ESR1—osteoporosis	1.09e-05	0.000455	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ENO1—osteoporosis	1.09e-05	0.000455	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PSMA2—osteoporosis	1.07e-05	0.000449	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PSMA5—osteoporosis	1.07e-05	0.000449	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP19A1—osteoporosis	1.06e-05	0.000443	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CALCA—osteoporosis	1e-05	0.000418	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IRS2—osteoporosis	9.95e-06	0.000416	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.83e-06	0.000411	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LEP—osteoporosis	9.73e-06	0.000407	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ESR1—osteoporosis	9.29e-06	0.000389	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ENO1—osteoporosis	9.12e-06	0.000381	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KL—osteoporosis	9.08e-06	0.00038	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PSMA5—osteoporosis	8.98e-06	0.000376	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PSMA2—osteoporosis	8.98e-06	0.000376	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IRS1—osteoporosis	8.68e-06	0.000363	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ADCY5—osteoporosis	8.65e-06	0.000362	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GPX1—osteoporosis	8.62e-06	0.000361	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—POMC—osteoporosis	8.36e-06	0.00035	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL6R—osteoporosis	8.16e-06	0.000341	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IGF1—osteoporosis	8.04e-06	0.000336	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—MTHFR—osteoporosis	7.96e-06	0.000333	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—MYC—osteoporosis	7.43e-06	0.000311	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP19A1—osteoporosis	7.29e-06	0.000305	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ADCY5—osteoporosis	7.11e-06	0.000297	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MTHFR—osteoporosis	6.54e-06	0.000273	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—POMC—osteoporosis	6.36e-06	0.000266	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IRS2—osteoporosis	6.22e-06	0.00026	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ADCY5—osteoporosis	5.95e-06	0.000249	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GPX1—osteoporosis	5.93e-06	0.000248	CbGpPWpGaD
Drospirenone—AR—Gene Expression—MYC—osteoporosis	5.66e-06	0.000237	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MTHFR—osteoporosis	5.48e-06	0.000229	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IRS1—osteoporosis	5.43e-06	0.000227	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IL6R—osteoporosis	5.1e-06	0.000213	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MYC—osteoporosis	4.83e-06	0.000202	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TGFB1—osteoporosis	4.82e-06	0.000202	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—POMC—osteoporosis	4.38e-06	0.000183	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL6—osteoporosis	3.63e-06	0.000152	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MYC—osteoporosis	3.02e-06	0.000126	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TGFB1—osteoporosis	3.02e-06	0.000126	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IL6—osteoporosis	2.27e-06	9.5e-05	CbGpPWpGaD
